Public-registry site landscape for NCT02784392, a Enteral Feeding Intolerance (EFI) study sponsored by Lyric Pharmaceuticals. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT02784392 (registry record) |
| Sponsor | Lyric Pharmaceuticals |
| Condition(s) | Enteral Feeding Intolerance (EFI) |
| Phase | PHASE2 |
| Listed sites | 5 |
| Site countries | United States, Netherlands, Spain |
Eichor generates a preliminary site-risk snapshot for NCT02784392 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →